18
Feb
La medicina del futuro è bio e “su misura”
La medicina del futuro è bio e “su misura”....
News
02FebHow Anemocyte is Changing History as a Biotech Manufacturing Organization (BMO)
How Anemocyte is Changing History as a Biotech Manufacturing Organization (BMO)...
- 24Jan
Anemocyte brings Italian excellence in the Cell and Gene Therapy sector to Phacilitate Leaders World 2020 in Miami
At the cutting edge of Cell and Gene therapy and a centre of excellence for the production of plasmids and non-viral solutions for genetic modifications, Anemocyte will be a key player at the leading sector event thanks to its expertise, dynamism and industrial cell and plasmid manufacturing facilities. ...
- 09Sep
Italian Biotech Raises €13M to Test Stem Cell Therapy for Cancer
The Italian biotech Genenta Science has raised €13.2M in a private round to fund two ongoing phase I/II trials of its stem cell therapy Temferon for blood and brain cancer....
- 16Jul
Anemocyte to expand its plasmid manufacturing capabilities
A new state-of-the-art facility dedicated to plasmid manufacturing will be in operation by August 2019 in Gerenzano, Italy. The new site will couple with the existing GMP facility active in the Cell and Gene (C&G) therapy space. With 800m2 (8,000 square feet) of cleanrooms, the two facilities of Anemocyte, the first Biotech Manufacturing Organisation (BMO), will address manufacturing needs of Somatic Cells, Non-Viral Modified Cells, Vesicles and Plasmids for Viral Vectors....
- 05Jul
Drones Land in the Cell and Gene Therapy Space
Cell and gene therapies could be flying high soon, joining the medical supplies, whole blood products, and even organs being transported by drones. In collaboration with RPS Aerospace, the Italy-based biotech company Anemocyte developed a remotely piloted drone system to securely transport final cell and gene therapy products from manufacturing sites to clinical centers....
- 25Jun
Technology Review: Gene Editing
Edition one of Phacilitate's Technology review series examines gene editing approaches by viral and no-viral methods and where to access these services....
- 20Jun
The Power of Perseverance: How Dendreon Bounced Back
The discussion moves onto goes onto the fine line between success and failure, examining the stories of Apollo 13, Thomas Edison and Elizabeth Gilbert, the author of Eat. Pray. Love. Dwayne explores failure and its negative connotations. Failure provides an opportunity to learn and to display passion to others, it’s an iteration on the road to success. In the immortal words of the great Thomas Edison…...
- 19Jun
Cell and Gene Therapy (CGT) Manufacturing Boom Roars Along
With a swell of R&D activity flowing into the development of cell and gene therapies over the past decade, a manufacturing shortage gripped the industry. This caused industry participants to express grave fears that the manufacturing shortage would threaten industry growth and lengthen time-to-market for these new types of living therapies....
- 03Jun
Perché fa sempre notizia il costo delle terapie per le malattie rare
È di pochi giorni fa la notizia dell’approvazione negli Stati Uniti di una terapia genica per l’atrofia muscolare spinale....
- 03Jun
Bluebird Bio’s First Gene Therapy Wins Approval in Europe
Bluebird Bio Inc.’s first gene therapy, a treatment for an inherited blood disorder, was cleared by European Union regulators, another milestone for the field following U.S. approval of Novartis AG’s $2.1 million treatment for a lethal childhood disease....
- 30May
Manufacturing Advanced Therapies in Europe
A comprehensive guide to Europe’s growing advanced therapies and viral vector manufacturing landscape....
- 27May
Meet the World’s First Biotech Manufacturing Organization, BMO
CRO, CMO, CDMO. These acronyms are well known in the biotech and pharma industry. But what is a BMO? If you haven’t heard of it, don’t worry. After all, there is only one BMO worldwide. We have set out to discover more about it, this biotech manufacturing organization....
13MayTerapie avanzate, così l’Italia si candida al ruolo di hub internazionale
L'Italia come Hub internazionale per le terapie avanzate. Uno scenario di sfide e opportunitá....
- 28Feb
Editoriale su Corriere Innovazione – 22/02/2019
In the editorial by Massimo Sideri on Corriere Innovazione he talks about politics and globalization of science, with reference to Excellula, Anemocyte's new headquarter for cell and gene advance therapies....
